# Seema Singhal

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/seema-singhal/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,162 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 65 |
| i10-index | 213 |
| Last Known Institution | All India Institute of Medical Sciences |
| OpenAlex ID | https://openalex.org/A5040773022 |
| ORCID iD | https://orcid.org/0000-0002-8644-7684 |
| Works | 504 |

## Researcher papers

- [Antitumor Activity of Thalidomide in Refractory Multiple Myeloma](https://scholariq.org/papers/antitumor-activity-of-thalidomide-in-refractory-multiple-myeloma/)
- [Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-pomalidomide-and-dexamethasone-for-patients-with-relapsed-or/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Hematopoietic Stem Cell Transplantation](https://scholariq.org/topics/hematopoietic-stem-cell-transplantation/)
- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [All India Institute of Medical Sciences](https://scholariq.org/institutions/all-india-institute-of-medical-sciences/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.